Medical condition
Clinical Trials
Clinical Trials is a medical condition tracked by NovaPharmaNews across 7 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- riluzole (PHARMACOR RILUZOLE) Nervous system (N07)
- idursulfase (ELAPRASE) Alimentary tract and metabolism (A16)
- cetrorelix (CETROTIDE) Systemic hormonal preparations (H01)
- lutropin alfa (LUVERIS) Genito-urinary system and sex hormones (G03)
- interferon beta-1a (BIFERONEX) Antineoplastic and immunomodulating agents (L03)
- interferon alfa-2b (INTRONA) Antineoplastic and immunomodulating agents (L03)
- follitropin alfa (BEMFOLA) Genito-urinary system and sex hormones (G03)
Latest Clinical Trials news
Friday Five: ASCO Takeaways, ADA Focus, China Deals & More – Clinical Trials
This week's Friday Five covers standout data from ASCO 2025, including Revolution Medicines' pancreatic cancer results, a preview of the upcoming ADA meeting, and a significant Eli Lilly deal in China. The roundup also highlights ADC safety findings and a new BMS-Hengrui collaboration, providing decision-useful insights for pharma stakeholders.
FDA Extends Comment Period for Real-Time Clinical Trials Pilot, AI Use in Studies
The FDA has extended the public comment period for its Real-Time Clinical Trials (RTCT) pilot and the associated Request for Information on AI-enabled optimization of early-phase trials. This move signals the agency's commitment to integrating AI into clinical trial oversight, with implications for drug development speed, cost, and regulatory strategy.
Uncertain FDA Leadership Raises Stakes in Clinical Trials: A Strategic Overview
Uncertainty surrounding FDA leadership is increasing the stakes for clinical trials, impacting drug approval pathways and strategic decision-making. Pharmaceutical teams and investors must navigate these changes to maintain development momentum.
FDA's Shifting Tides: Navigating Clinical Trials Amidst Regulatory Uncertainty
The FDA is implementing a modern approach to real-time clinical trials (RTCT), allowing scientists to monitor safety signals and endpoints as trials progress. This initiative follows a period where the agency halted an average of 664 experimental drug trials annually from 2017-2021, highlighting a complex regulatory environment.
Navigating Human Research: Mass General Brigham's IRB Guidance for Ethical Clinical Trials
This whitepaper summarizes Mass General Brigham's Institutional Review Board (IRB) Guidance, offering essential information for researchers and institutions involved in human subject research.
CDC Prioritizes Ebola Containment, Highlighting Critical Role of Clinical Trials
The Centers for Disease Control and Prevention (CDC) has identified the containment of Ebola as its foremost priority, emphasizing the indispensable role of ongoing clinical trials in developing and deploying effective countermeasures. This directive signals a critical juncture for public health preparedness and the pharmaceutical industry's response to infectious disease threats.
Accelerating Drug Development: FDA's AI Clinical Trials RFI Guide
The FDA has released a guide aimed at accelerating drug development through the use of AI in clinical trials. This article outlines key takeaways and implications for pharmaceutical teams.
Commissioner's National Priority Voucher Pilot Program: Clinical Trials Insights
This article analyzes the CNPV Pilot Program's implications for clinical trials and investment strategies in the pharmaceutical sector.